TRELEGY ELLIPTA Drug Patent Profile

When do Trelegy Ellipta patents expire, and what generic alternatives are available?

Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-nine patent family members in forty-nine countries.

The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Trelegy Ellipta

Trelegy Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2030. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRELEGY ELLIPTA

International Patents:	199
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TRELEGY ELLIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRELEGY ELLIPTA
What excipients (inactive ingredients) are in TRELEGY ELLIPTA?	TRELEGY ELLIPTA excipients list
DailyMed Link:	TRELEGY ELLIPTA at DailyMed

See drug prices for TRELEGY ELLIPTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRELEGY ELLIPTA

Constraining patent/regulatory exclusivity:

9,750,726

NDA:

209482

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRELEGY ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE2
Baylor Research Institute	Phase 4
GlaxoSmithKline	Phase 4

See all TRELEGY ELLIPTA clinical trials

Pharmacology for TRELEGY ELLIPTA

Drug Class	Anticholinergic Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for TRELEGY ELLIPTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	200 mcg/62.5 mcg/ 25 mcg	209482	1	2026-03-19
TRELEGY ELLIPTA	Powder for Inhalation	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	100 mcg/62.5 mcg/ 25 mcg	209482	1	2025-11-26

US Patents and Regulatory Information for TRELEGY ELLIPTA

TRELEGY ELLIPTA is protected by six US patents.

This potential generic entry date is based on patent 9,750,726.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	11,090,294
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	7,488,827		Y	Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	7,488,827		Y	Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	9,750,726		Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	9,750,726		Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	12,396,986		Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	8,746,242*PED				Y

Expired US Patents for TRELEGY ELLIPTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	7,629,335
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020	8,183,257
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	6,537,983
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	7,776,895
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020	7,776,895
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020	8,309,572
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	6,878,698

International Patents for TRELEGY ELLIPTA

When does loss-of-exclusivity occur for TRELEGY ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Ukraine

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELEGY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2010326798
Australia	2014204459
Australia	2016262698
Australia	2017238392
Australia	2018282427
Australia	2021204302
Australia	2023219901

Supplementary Protection Certificates for TRELEGY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	91429	Luxembourg		91429, EXPIRES: 20230111
1305329	CA 2008 00022	Denmark
1305329	300343	Netherlands		300343, 20210803, EXPIRES: 20230110
1305329	SPC011/2008	Ireland		SPC011/2008: 20081105, EXPIRES: 20230110
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329	C01305329/01	Switzerland		PRODUCT NAME: FLUTICASON FUROAT; REGISTRATION NUMBER/DATE: SWISSMEDIC 57968 19.12.2007
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116

TRELEGY ELLIPTA Market Dynamics and Financial Trajectory: exclusivity drivers, payer pressure, and generic/biosimilar risk

Last updated: July 27, 2026

TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) is an entrenched inhaled triple-therapy franchise in COPD and a fast-scaling option in certain asthma segments. Its financial trajectory is shaped by (1) line-extension uptake versus LAMA/LABA and ICS/LABA, (2) formulary design and copay dynamics driven by PBM contracting, (3) competitive pressure from other triple-therapy inhalers and biologic adoption in higher-acuity asthma, and (4) a relatively long runway from key regulatory and patent exclusivity milestones that constrain immediate generic entry.

---

What is TRELEGY ELLIPTA’s market position in COPD and asthma, and who is taking share?

TRELEGY ELLIPTA is positioned as an inhaled once-daily triple therapy delivering an inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting beta-agonist (LABA). In COPD, it competes most directly against other triple-inhaler regimens and against step-up pathways from dual therapy to triple therapy after exacerbations.

COPD: where it wins

• Higher share of prescriptions is typically concentrated among patients with a history of exacerbations who move from ICS/LABA or LAMA/LABA to triple therapy.
• Clinician behavior tends to favor once-daily fixed-dose combinations for adherence and simplification.

Asthma: where it is used

TRELEGY ELLIPTA is not an across-the-board first-line asthma option; adoption is influenced by phenotyping, step-therapy rules, and payer criteria. Growth in asthma is typically incremental relative to COPD unless a specific payer-driven asthma contracting advantage exists.

Competitive set

Key competitive pressure comes from:

• Other fixed-dose once-daily triple inhalers (notably GSK’s Breo-based strategy is different, but triple offerings include products from AstraZeneca, Novartis, and others depending on formulation).
• Dual inhalers used in earlier lines that can capture “step-up avoidance.”
• Biologics for asthma subtypes in patients who meet criteria; biologics shift a portion of spend away from inhaled escalation for severe asthma.

Business implication: In COPD, the main battleground is formulary placement and step-therapy design that determines whether payers push patients to triple therapy sooner or delay it.

---

What drives TRELEGY ELLIPTA revenue: demand, pricing, and channel mix?

Revenue trajectory for inhaled respiratory franchises typically tracks four levers.

1) Prescribing intensity and persistence

• Once-daily triple therapy benefits from persistent use when patients remain stable and inhaler technique is retained.
• Discontinuation often clusters around payer switches, high out-of-pocket costs, or loss of perceived efficacy after exacerbations.

2) Net price pressure

As triple therapy becomes a contracting commodity in many formularies, net pricing compresses via:

• PBM rebate programs,
• preferred-tier status changes,
• contract-specific patient-cost arrangements.

3) Channel mix

• Retail vs specialty pharmacy mix matters less than for oncology, but channel behavior still shifts with payer policy and managed-care controls.
• Durable market share in respiratory is often strongest through large MA and commercial networks that standardize formularies.

4) Product lifecycle management

Within inhaled respiratory, lifecycle actions include:

• optimizing label-based prescribing
• consolidating support programs
• targeting high-likelihood exacerbator cohorts

Business implication: Even when unit growth slows, net retention can hold revenue if formulary positioning stays favorable and switch triggers are limited.

---

When does TRELEGY ELLIPTA lose exclusivity, and how does that affect the financial timeline?

A drug’s financial trajectory hinges on two timelines:

1. regulatory exclusivity (market-authorization protection),
2. patent expiration and patent litigation outcomes (generic entry constraints).

Key decision points

• If major patents expire while litigation stays unresolved, generic or “at-risk” entry risk rises.
• If settlements or licensing arrangements lock generics out until a later date, revenue can be extended by controlling entry.

Practical financial effect

For a triple-inhaler with entrenched prescribing, the revenue impact of exclusivity loss usually starts with:

• expected inventory planning by manufacturers,
• formulary renegotiation by payers after first generic signals,
• rapid share dilution if multiple entrants launch.

Business implication: TRELEGY ELLIPTA’s financial trajectory remains more stable than inhalers whose exclusivity has shorter remaining windows or where patent estates are weak.

---

What patents protect TRELEGY ELLIPTA, and which ones matter for generic entry?

TRELEGY ELLIPTA’s patent estate typically includes multiple families spanning:

• composition of matter,
• formulation and particle/solvate-related details,
• device and delivery parameters,
• method-of-use for COPD and/or asthma indications,
• manufacturing processes for the triple combination.

How patent estate strength translates to revenue

• If composition-of-matter protection remains active, generics face high barriers.
• If only formulation or method-of-use claims remain at the end of the timeline, generics can sometimes design around depending on claim scope and the label they seek.

Paragraph IV and “skinny label” risk

Generic entry pressure is driven by:

• paragraph IV filings with challenge strategies aimed at the closest expiring claims,
• whether ANDA filers pursue full-label approvals or carve-outs that reduce risk,
• settlement terms that can delay or limit launch.

Business implication: The most relevant estate components are the ones that dictate the earliest plausible launch date for a lab-ready ANDA pathway.

---

What Orange Book status does TRELEGY ELLIPTA have, and what does it imply for generic timing?

Orange Book listings map to patent families tied to the approved NDA and listed drugs. For a high-throughput brand, listings typically include:

• multiple patent numbers with different expiration dates,
• multiple claim types under each expiration timeline.

Featured-snippet summary

• The earliest expiration date in the Orange Book listing set sets the first time window where ANDA challengers can realistically pressure entry.
• Later-expiring patents sustain barriers even if early claims fall.

Business implication: Investors and litigation stakeholders typically forecast market impact using the earliest “meaningful” claim expiration plus the expected litigation and settlement schedule.

---

Has TRELEGY ELLIPTA faced Paragraph IV challenges or ANDA litigation, and what settlement outcomes matter?

Generic entry risk is shaped by:

• whether ANDA filers challenge the earliest-listed patents,
• whether court outcomes or settlements delay launch dates,
• whether “first generic” entrants secure favorable payer access.

What to track in litigation

• complaint filing dates and triggering events,
• court rulings on claim construction,
• settlement structures that include launch date triggers, payment terms, or licensing provisions.

Business implication: A settlement that ties generic entry to a later date can extend revenue even after early patent expiration windows open.

---

Which companies are most likely to launch generic TRELEGY ELLIPTA first?

Generic first-entry usually comes from:

• established inhalation-focused ANDA manufacturers with capacity for dry powder inhaler (DPI) and combination formulation work,
• firms with prior regulatory experience in complex inhaler portfolios.

Market mechanics of first entry

• First launchers often obtain the fastest formulary traction.
• A second wave occurs once payers negotiate post-entry rebates and multiple SKUs create competitive bidding.

Business implication: The number of ANDA entrants and the speed of payer contracting drive the magnitude of share loss.

---

How does TRELEGY ELLIPTA compare with other COPD triple therapies on likely commercial outcomes?

Inhaled triple therapy competition tends to resemble a “class premium” race until contracting compresses net prices.

Key comparative dimensions

• Device parity and user preference
• Exacerbation reduction evidence in labeled populations
• Payer tiering and prior authorization burden
• Conversion pathways from dual therapy

Commercial pattern across the class

• Strongest sustained demand usually follows when the product holds a preferred formulary tier and has lower administrative friction.
• Outcomes deteriorate faster when payers standardize across triple options and only award preference on net price.

Business implication: TRELEGY ELLIPTA’s financial trajectory depends as much on PBM contracting outcomes as on clinical differentiation.

---

What payer and PBM dynamics are most likely to impact TRELEGY ELLIPTA net revenue?

Net revenue in respiratory brands is payer-driven.

Formulary placement

• Preferred tier placement supports stable prescription volume.
• Tier downgrades and tighter criteria can cause abrupt declines.

Utilization management

• Step therapy requirements, prior authorization, and quantity limits can delay conversions to triple therapy.
• Criteria targeting frequent exacerbators can limit growth but can also protect economics by concentrating high-value patients.

Copay design

• Copay card usage and patient cost-sharing programs can sustain demand, but they become less effective if PBMs restrict affordability programs in higher-income managed care populations.

Business implication: Revenue sensitivity is highest around contract renewals and formulary redesign cycles.

---

What is the financial trajectory of TRELEGY ELLIPTA: growth drivers, maturity signals, and margin risk?

The observed financial trajectory for successful inhaled franchises usually passes through three phases:

Phase 1: Expansion (ramp)

• Adoption from ICS/LABA and LAMA/LABA to triple therapy.
• Evidence-led conversion and stable copay mechanics.

Phase 2: Maturity (steady demand with price pressure)

• Unit growth slows; net price declines increasingly drive revenue variability.
• PBM contracting reduces gross-to-net spread.

Phase 3: Late-cycle risk

• Patent and exclusivity windows shrink.
• Market expects generic entrants; payers anticipate substitution.

Business implication: TRELEGY ELLIPTA’s late-cycle risk profile depends on how close the earliest meaningful patent expirations are relative to settlement outcomes and how concentrated its formulary positions are.

---

What manufacturing and supply constraints could affect TRELEGY ELLIPTA sales?

Inhalers face distinct supply risks:

• DPI component sourcing
• formulation blending consistency
• packaging line constraints
• device assembly throughput

Supply issues can show up as:

• short-term fill rate problems,
• channel inventory swings,
• temporary share loss to competing inhalers.

Business implication: Even when demand is intact, supply constraints can accelerate competitive switching, making post-constraint recovery harder.

---

What biosimilar risk exists for TRELEGY ELLIPTA?

TRELEGY ELLIPTA is a small-molecule inhaled combination product and does not have biosimilar risk in the way biologics do. The relevant competitive substitute risk is generic substitution after patent and exclusivity barriers fall.

---

What key regulatory events could shift TRELEGY ELLIPTA’s market access?

Regulatory events that matter commercially:

• label updates expanding eligible populations,
• safety communications that affect prescribing patterns,
• REMS-type requirements (if any) and postmarketing commitments.

Business implication: Label changes can open new patient segments but only translate into revenue if payers update criteria quickly.

---

Key takeaways

• TRELEGY ELLIPTA’s market dynamics are driven mainly by formulary contracting, step-up rules, and persistence in COPD triple-therapy pathways.
• Revenue stability depends on how long exclusivity and patent barriers remain enforceable and whether ANDA litigation and settlements delay generic substitution.
• Late-cycle financial risk is less about “biosimilar” dynamics and more about the timing and breadth of generic inhaler entry and subsequent PBM rebate renegotiations.
• The magnitude of revenue erosion after patent expiry will be determined by first-to-market launch behavior, number of entrants, and how aggressively payers convert patients to lower-cost alternatives.

---

FAQs

1) How quickly do payers switch COPD patients after generic triple inhalers launch?

Answer: Switching typically accelerates at contract renewal points, with the biggest movement tied to tier placement and prior authorization tightening after the first generic signal.

2) Do step-therapy restrictions usually protect TRELEGY ELLIPTA during patent challenges?

Answer: They can slow step-up conversion away from triple therapy, but net effect depends on whether the triple category is standardized on a lower-cost preferred option.

3) What is the most common formulation strategy generics use to design around triple-inhaler patents?

Answer: ANDA filers often target formulation or method-of-use claim scopes while keeping the active ingredient set consistent and aiming for design-around for device, particle properties, or process claims.

4) What is the biggest driver of net price declines for inhaled triple therapy?

Answer: PBM contracting that rebalances preferred tier status through rebate reductions and competitive benchmarking once multiple therapeutically equivalent options exist.

5) When investors model TRELEGY ELLIPTA downside, what variables dominate?

Answer: The earliest “meaningful” patent expiration date (plus litigation/settlement delays), expected launch calendar for first ANDA entrant(s), and formulary adoption speed of generic competitors.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. FDA. Patent and Exclusivity Information for Approved Products. https://www.fda.gov/drugs/